Rewiring Cancer's Metabolic Engine

Chemoresistance in non-small cell lung cancer (NSCLC) is a major obstacle in treating the disease. When patients are treated with platinum drugs, their cancer often becomes resistant to these treatments. Researchers have been searching for ways to overcome this resistance, and a new study has shed light on a potential solution.

The study focused on a protein called C/EBPβ, which has two different forms: LAP and LIP. These forms can affect how cancer cells respond to chemotherapy by influencing the expression and activity of a group of proteins called ABC efflux transporters. By studying how LAP and LIP work together, researchers found that they can reprogram the metabolism of cancer cells, making them more resistant to chemotherapy.

To investigate this further, the researchers created cells that overexpressed either LAP or LIP and tested their sensitivity to chemotherapy. They also analyzed the cells' metabolome and lipidome to see how they were affected by the different forms of C/EBPβ. The results showed that LAP increased the levels of certain proteins involved in fatty acid oxidation, a process that provides energy to cells. This increase in fatty acid oxidation made the cancer cells more resistant to chemotherapy.

On the other hand, LIP had the opposite effect, reducing the levels of these proteins and making the cancer cells more sensitive to chemotherapy. The researchers also found that inhibiting fatty acid oxidation with a drug called etomoxir could overcome chemoresistance in cancer cells. This is a promising finding, as it suggests that targeting the metabolic pathways of cancer cells could be a new way to treat the disease.